Deltec Asset Management LLC bought a new stake in Heron Therapeutics Inc (NASDAQ:HRTX) during the 4th quarter, HoldingsChannel reports. The firm bought 117,000 shares of the biotechnology company’s stock, valued at approximately $2,118,000.
Several other institutional investors have also recently bought and sold shares of the company. Janus Henderson Group PLC bought a new position in shares of Heron Therapeutics in the 2nd quarter valued at $78,134,000. Perceptive Advisors LLC acquired a new stake in shares of Heron Therapeutics in the 3rd quarter valued at about $5,329,000. Vanguard Group Inc. grew its stake in shares of Heron Therapeutics by 11.8% in the 2nd quarter. Vanguard Group Inc. now owns 2,096,465 shares of the biotechnology company’s stock valued at $29,036,000 after buying an additional 221,362 shares during the period. Rubric Capital Management LP grew its stake in shares of Heron Therapeutics by 11.8% in the 3rd quarter. Rubric Capital Management LP now owns 1,900,000 shares of the biotechnology company’s stock valued at $30,685,000 after buying an additional 200,000 shares during the period. Finally, Chartwell Investment Partners LLC acquired a new stake in shares of Heron Therapeutics in the 3rd quarter valued at about $2,340,000. 98.37% of the stock is currently owned by institutional investors.
HRTX has been the subject of a number of analyst reports. Mizuho reiterated a “buy” rating and set a $28.00 price target on shares of Heron Therapeutics in a research note on Tuesday, November 7th. Cowen reissued a “buy” rating and set a $40.00 target price on shares of Heron Therapeutics in a research report on Monday, November 6th. Cantor Fitzgerald reissued a “buy” rating and set a $31.00 target price on shares of Heron Therapeutics in a research report on Thursday, November 2nd. Oppenheimer started coverage on shares of Heron Therapeutics in a research report on Monday, October 30th. They set a “buy” rating and a $27.00 target price on the stock. Finally, Zacks Investment Research raised shares of Heron Therapeutics from a “hold” rating to a “buy” rating and set a $18.00 target price on the stock in a research report on Wednesday, November 22nd. Three analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $28.82.
Shares of Heron Therapeutics Inc (HRTX) traded up $0.20 during mid-day trading on Monday, reaching $21.85. 209,978 shares of the company’s stock were exchanged, compared to its average volume of 1,055,816. The company has a market cap of $1,180.00, a PE ratio of -5.71 and a beta of 1.87. The company has a debt-to-equity ratio of 0.62, a current ratio of 2.12 and a quick ratio of 2.02. Heron Therapeutics Inc has a 1-year low of $12.70 and a 1-year high of $24.80.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Monday, November 6th. The biotechnology company reported ($0.77) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.10. The business had revenue of $8.57 million during the quarter, compared to the consensus estimate of $8.12 million. Heron Therapeutics had a negative net margin of 831.89% and a negative return on equity of 385.11%. analysts forecast that Heron Therapeutics Inc will post -3.37 EPS for the current fiscal year.
In other Heron Therapeutics news, VP Kimberly Manhard sold 7,584 shares of the business’s stock in a transaction on Wednesday, January 10th. The shares were sold at an average price of $20.00, for a total value of $151,680.00. Following the completion of the sale, the vice president now directly owns 7,584 shares of the company’s stock, valued at $151,680. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders own 19.93% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Deltec Asset Management LLC Invests $2.12 Million in Heron Therapeutics Inc (HRTX)” was originally posted by Stock Observer and is the property of of Stock Observer. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.thestockobserver.com/2018/02/05/deltec-asset-management-llc-invests-2-12-million-in-heron-therapeutics-inc-hrtx.html.
Heron Therapeutics Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
Want to see what other hedge funds are holding HRTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Heron Therapeutics Inc (NASDAQ:HRTX).
Receive News & Ratings for Heron Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.